Rani Therapeutics Holdings, Inc. (RANI): Total Liabilities
$17.11M
As of 2025-12-31
$12.86M
As of 2026-06-30
-20.5%
3-year compound annual growth
+16.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $17.11M | -48.4% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $33.14M | +2.1% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $32.47M | -4.6% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $34.02M | n/m | 2024-03-20, Balance as of period end |
| 2021-12-31 | $2.64M | -67.2% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $8.04M | n/a | 2022-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $17.11M | -48.4% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $28.89M | +7.5% |
| Bio Essence Corp (BIOE) | 2025-12-31 | $2.50M | -23.2% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.10M | +34.7% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $128.86M | +21.9% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $37.17M | +21.3% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $2.53M | +67.1% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $37.52M | +74.3% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $2.42M | -6.4% |
Compare RANI, NRXP, BIOE, ATXI side by side · Screen every company in Pharmaceutical Preparations ↗